For help on how to get the results you want, see our search tips.
518 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Withdrawn applications Remove Withdrawn applications filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Medicine type
Additional monitoring Remove Additional monitoring filter
Orphan medicine Remove Orphan medicine filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Semglee (updated)
insulin glargine, Diabetes Mellitus
Date of authorisation: 23/03/2018,
, 
, Revision: 6, Authorised, Last updated: 14/01/2022
-
List item
Human medicine European public assessment report (EPAR): Xaluprine (previously Mercaptopurine Nova Laboratories) (updated)
6-mercaptopurine monohydrate, Leukemia, Lymphoid
Date of authorisation: 09/03/2012,
, Revision: 13, Authorised, Last updated: 14/01/2022
-
List item
Human medicine European public assessment report (EPAR): Granupas (previously Para-aminosalicylic acid Lucane) (updated)
Para-aminosalicylic acid, Tuberculosis
Date of authorisation: 07/04/2014,, Revision: 9, Authorised, Last updated: 13/01/2022
-
List item
Human medicine European public assessment report (EPAR): Quinsair (updated)
levofloxacin, Cystic Fibrosis; Respiratory Tract Infections
Date of authorisation: 25/03/2015,, Revision: 14, Authorised, Last updated: 13/01/2022
-
List item
Human medicine European public assessment report (EPAR): Tavlesse (updated)
Fostamatinib disodium, Thrombocytopenia
Date of authorisation: 09/01/2020,, Revision: 4, Authorised, Last updated: 13/01/2022
-
List item
Human medicine European public assessment report (EPAR): Elzonris (updated)
tagraxofusp, Lymphoma
Date of authorisation: 07/01/2021,, , 
, Revision: 3, Authorised, Last updated: 13/01/2022
-
List item
Human medicine European public assessment report (EPAR): Artesunate Amivas (updated)
artesunate, Malaria
Date of authorisation: 22/11/2021,, , Authorised, Last updated: 13/01/2022
-
List item
Human medicine European public assessment report (EPAR): Vemlidy (updated)
tenofovir alafenamide fumarate, Hepatitis B
Date of authorisation: 09/01/2017,, Revision: 13, Authorised, Last updated: 12/01/2022
-
List item
Human medicine European public assessment report (EPAR): Ontozry (updated)
cenobamate, Epilepsy
Date of authorisation: 26/03/2021,, Revision: 3, Authorised, Last updated: 12/01/2022
-
List item
Human medicine European public assessment report (EPAR): Hulio (updated)
adalimumab, Hidradenitis Suppurativa; Psoriasis; Uveitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic
Date of authorisation: 17/09/2018,, , Revision: 10, Authorised, Last updated: 12/01/2022
-
List item
Human medicine European public assessment report (EPAR): Kengrexal (updated)
cangrelor, Acute Coronary Syndrome; Vascular Surgical Procedures
Date of authorisation: 23/03/2015,, Revision: 11, Authorised, Last updated: 12/01/2022
-
List item
Human medicine European public assessment report (EPAR): Scenesse (updated)
afamelanotide, Protoporphyria, Erythropoietic
Date of authorisation: 22/12/2014,, , , Revision: 8, Authorised, Last updated: 12/01/2022
-
List item
Human medicine European public assessment report (EPAR): Ogivri (updated)
trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 12/12/2018,, , Revision: 8, Authorised, Last updated: 12/01/2022
-
List item
Human medicine European public assessment report (EPAR): Suliqua (updated)
insulin glargine, lixisenatide, Diabetes Mellitus, Type 2
Date of authorisation: 11/01/2017,, Revision: 8, Authorised, Last updated: 12/01/2022
-
List item
Human medicine European public assessment report (EPAR): Revestive (updated)
teduglutide, Malabsorption Syndromes
Date of authorisation: 30/08/2012,, , Revision: 17, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Increlex (updated)
Mecasermin, Laron Syndrome
Date of authorisation: 02/08/2007,, , Revision: 24, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Heplisav B (updated)
hepatitis B surface antigen, Hepatitis B
Date of authorisation: 18/02/2021,, Revision: 1, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Endometrial Neoplasms
Date of authorisation: 17/07/2015,, Revision: 41, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Minjuvi (updated)
Tafasitamab, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 26/08/2021,, , 
, Revision: 2, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Deltyba (updated)
Delamanid, Tuberculosis, Multidrug-Resistant
Date of authorisation: 27/04/2014,
Date of refusal: 25/07/2013,, , , Revision: 18, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Venclyxto (updated)
Venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 04/12/2016,, Revision: 12, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Cerdelga (updated)
eliglustat, Gaucher Disease
Date of authorisation: 19/01/2015,, , Revision: 13, Authorised, Last updated: 11/01/2022
-
List item
Human medicine European public assessment report (EPAR): Prevymis (updated)
Letermovir, Cytomegalovirus Infections
Date of authorisation: 08/01/2018,, , Revision: 10, Authorised, Last updated: 10/01/2022
-
List item
Human medicine European public assessment report (EPAR): Ibrance (updated)
palbociclib, Breast Neoplasms
Date of authorisation: 09/11/2016,, Revision: 13, Authorised, Last updated: 10/01/2022
-
List item
Human medicine European public assessment report (EPAR): Rizmoic (updated)
Naldemedine tosilate, Constipation
Date of authorisation: 18/02/2019,, Revision: 6, Authorised, Last updated: 10/01/2022